A 48-Year-Old Obese Man with a 3 cm Liver Lesion and a History of Hemochromatosis and Lymphoma

Gabriel Levi; Moueen Bu-Ghanim; Ruliang Xu; Emil Cohen; Chaim Abittan; Sasan Roayaie

doi:10.1055/s-2004-832944

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2004; 24(3): 327-332
DOI: 10.1055/s-2004-832944

DIAGNOSTIC PROBLEMS IN HEPATOLOGY

A 48-Year-Old Obese Man with a 3 cm Liver Lesion and a History of Hemochromatosis and Lymphoma

Gabriel Levi¹ , Moueen Bu-Ghanim¹ , Ruliang Xu¹ , Emil Cohen² , Chaim Abittan³ , Sasan Roayaie⁴

¹The Lillian and Henry M. Stratton-Hans Popper Department of Pathology, New York, NY
²Department of Radiology, Mount Sinai School of Medicine, New York, NY
³Department of Internal Medicine, Division of Gastroenterology, St. Francis Hospital, Roslyn, New York
⁴Recanati-Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NEW YORK

Abstract

Full Text

References

REFERENCES

1 Bergquist A, Ekbom A, Olsson R et al.. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002; 36 321-327
2 Boberg K M, Bergquist A, Mitchell S et al.. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002; 37 1205-1211
3 Genetic haemochromatosis . Report of a meeting of physicians and scientists at the Royal Free Hospital School of Medicine. Lancet. 1997; 349 1688-1693
4 Leggett B A, Halliday J W, Brown N N et al.. Prevelance of haemochromatosis amongst asymptomatic Australians. Br J Haematol. 1990; 74 525-530
5 Feder J N, Gnirke A, Thomas W et al.. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13 399-408
6 Britto M R, Thomas L A, Balaratnam N, Griffiths A P, Duane P D. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand J Gastroenterol. 2000; 35 889-893
7 Gelatti U, Donato F, Tagger A et al.. Etiology of hepatocllular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol. 2003; 98 907-914
8 Morcos M, Dubois S, Bralet M et al.. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol. 2001; 116 738-743
9 Cauza E, Peck-Radosavlijevic M, Ulrich-Pur H et al.. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol. 2003; 98 442-447
10 Orii T, Ohkohchi N, Sasaki K et al.. Cholangiocarcinoma arising from pre-existing biliary hamartoma of liver-report of a case. Hepatogastroenterology. 2003; 50 333-336
11 Parkin D M, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev. 1993; 2 537-544
12 Kurathong S, Lerdverasirikul P, Wongpaitoon V et al.. Opisthorchis viverrini infection and cholangiocarcinoma, a prospective, case-controlled study. Gastroenterology. 1985; 89 151-156
13 Schwartz D A. Cholangiocarcinoma associated with liver fluke infection: a preventable source of morbidity in Asian immigrants. Am J Gastroenterol. 1986; 81 76-79
14 Leung J W, Yu A S. Hepatolithiasis and biliary parasites. Baillieres Clin Gastroenterol. 1997; 11 681-706
15 Chen M F, Jan Y Y, Jeng L B et al.. Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg. 1999; 6 136-141
16 Lee C C, Wu C Y, Chen G H. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma?. J Gastroenterol Hepatol. 2002; 17 1015-1020
17 Chijiiwa K, Ohtani K, Noshiro H et al.. Cholangiocellular carcinoma depending on the kind of intrahepatic calculi in patients with hepatolithiasis. Hepatogastroenterology. 2002; 49 96-99
18 Tocchi A, Mazzoni G, Liotta G et al.. Late development of bile duct cancer in patients who had biliary enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg. 2001; 234 210-214
19 Chapman R W. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999; 10(Suppl 4) 308-311
20 Lee F I, Tharakan J, Vasudev K S, Isaacs P E. Malignant hepatic tumours associated with previous exposure to Thorotrast: four cases. Eur J Gastroenterol Hepatol. 1996; 8 1121-1124
21 Kuper H, Lagiou P, Mucci L A et al.. Risk factors for cholangiocarcinoma in a low risk Caucasian population. Soz Praventivmed. 2001; 46 182-185
22 Temizkan M, Ouwendijk J T, Middelkoop M P et al.. A young female with a cholangiocarcinoma in the past: is pregnancy allowed?. Acta Gastroenterol Latinoam. 1996; 26 31-34
23 Key T J, Appleby P N, Reeves G K et al.. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003; 95 1218-1226
24 Bastounis E A, Karayiannakis A J, Syrigos K et al.. Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res. 1998; 30 43-47
25 Sasaki M, Tsuneyama K, Ishikawa A, Nakanuma Y. Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. Hum Pathol. 2003; 34 1337-1344
26 Kuper H, Ye W, Broome U et al.. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism or cirrhosis. Hepatology. 2001; 34 714-718
27 Donato F, Gelatti U, Tagger A et al.. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001; 12 959-964
28 Jaiswal M, Larusso N F, Burgart L J, Gores G J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; 60 184-190
29 Terada T, Ashida K, Endo K et al.. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology. 1998; 33 325-331
30 Ozaki S, Harad K, Sanzen T et al.. In situ nucleic acid detection of human teolmerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion. Hepatology. 1999; 30 914-919
31 Terada T, Ueyama J, Ukita Y, Ohta T. Protein expression of double-stranded RNA-activated protein kinase (PKR) in intrahepatic bile ducts in normal adult livers, fetal livers, primary biliary cirrhosis, heptolithiasis and intrahepatic cholangiocarcinoma. Liver. 2000; 20 450-457
32 Lee K T, Liu T S. Expression of transforming growth factor betas and their signaling receptors in stone-containin intrahepatic bile ducts and cholangiocarcinoma. World J Surg. 2003; 27 1143-1148
33 Sasaki M, Huang S F, Chen M F et al.. Decrease of deleted in malignant brain tumour-1 (DMBT-1) expression is a crucial late event in intrahepatic cholangiocarcinoa. Histopathology. 2003; 43 340-346
34 Sasaki M, Tsuneyama K, Nakanuma Y. Aberrant expression of trefoil family 1 in biliary epithelium in hepatolithiasis and cholangiocarcinoma. Lab Invest. 2003; 83 1403-1413
35 Orikasa H, Ohyama R, Tsuka N, Eyden B P, Yamazaki K. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol. 2001; 33 195-200
36 Tsuneyama K, Kaizaki Y, Doden K et al.. Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non-cirrhotic liver. Pathol Int. 2003; 53 90-97
37 Katoh M, Takeuchi K, Murahima N et al.. Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report. Jpn J Clin Oncol. 1994; 24 111-115
38 Britto M R, Thomas L A, Balaratnam N, Griffiths A P, Duane P D. Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand J Gastroenterol. 2000; 35 889-893
39 Lau S K, Prakash S, Geller S A, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002; 33 1175-1181

Gabriel LeviM.D.

The Lillian and Henry M. Stratton-Hans Popper Department of Pathology

Box 1194, One Gustave L. Levy Place

New York, NY 10029

Email: Gabriel.Levi@msnyuhealth.org